New study aims to spot liver damage with a simple blood draw
NCT ID NCT07359742
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is looking for new blood markers that could show how much scarring (fibrosis) is in the liver of people with chronic liver disease. Researchers will compare these markers to current tests like FibroScan and liver biopsy. The goal is to find a more accurate and less invasive way to detect liver damage early.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a simple blood test that detects liver scarring earlier and more accurately than current methods.
- What could go wrong
- This is an observational study, not a treatment trial. It may not find a reliable new marker, and results may not apply to all liver disease types.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LIVER DISEASE (CLD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UZ Brussel
RECRUITINGBrussels, 1090, Belgium
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a vitamin d cocktail fix deficiency in kids with liver disease?
- New liver drug AD-230 gets first human test – with or without food?
- New ultrasound technique could replace needle biopsy for liver disease
- Ultrasound may replace scopes for bleeding risk in liver patients
- New liver drug candidate AD-230 enters first human tests
- Liver biopsy showdown: EUS or needle – patients decide!